Key Facts

Latest information about our company.

Global Business

Updated November 2023

Chief Executive Officer:
Headquarters:
Princeton, New Jersey, USA
Business:
Biopharmaceuticals
Web Address:
NYSE Listing:
BMY
Full-year Revenue (2020):
$42.5B
R&D Investment (2020):
$11.1 billion which included the discovery and development of new medicines for patients
Principal Locations:
BMS Canada At A Glance
BMS Canada At a Glance

Local Business

Updated June 2023

General Manager:
Elaine Phillips
Head Office:
Montreal, Quebec, Canada
Address:
2344 Alfred-Nobel,
Suite 300
Saint-Laurent, QC
H4S 0A4
CANADA
Areas of Focus:
Oncology
Hematology
Immunology
Cardiovascular disease
Key products :

BREYANZITM (lisocabtagene maraleucel)
CAMZYOSTM (mavacamten capsules)
ELIQUIS® (apixaban)
ONUREG ® (azacitidine tablets)
OPDIVO® (nivolumab)
OPDUALAGTM (nivolumab and relatlimab for injection)
ORENCIA® (abatacept)
POMALYST® (pomalidomide)
REBLOZYL® (luspatercept)
REVLIMID® (lenalidomide)
SOTYKTUTM (deucravacitinib)
YERVOY® (ipilimumab)
ZEPOSIA® (ozanimod)